Picard Medical Reports 39% Revenue Growth in Q2 2026 Despite Net Loss

Picard Medical, Inc. reported a significant increase in revenue for the second quarter of 2026, with total revenues reaching $2.954 million, a 39% increase compared to $2.131 million in the same period of 2025. For the first half of 2026, revenues totaled $4.104 million, up 50% from $2.744 million in the first half of 2025. The growth was primarily driven by a 41% increase in product sales, which amounted to $3.878 million, and the introduction of rental revenues of $226,000. Despite this revenue growth, the company reported a net loss of $5.660 million for the quarter, an improvement from a net loss of $6.724 million in the prior year.

The financial performance of Picard Medical reflects a notable shift in operational metrics. The gross profit for the second quarter was $616,000, compared to a loss of $127,000 in the same quarter of the previous year. However, total operating expenses surged to $5.245 million, a 55% increase from $3.394 million in the prior year, largely due to increased research and development costs and higher selling, general, and administrative expenses. The company’s operating loss for the quarter was $4.629 million, compared to a loss of $3.521 million in the same quarter of 2025.

In terms of strategic developments, Picard Medical has been actively pursuing the development of its next-generation product, the Emperor Total Artificial Heart (TAH). The company has completed a series of acute in vivo implant studies and presented new data at the American Society for Artificial Internal Organs conference. This initiative is part of a broader strategy to enhance its product offerings and market position in the medical device sector. Additionally, the company has expanded its geographic reach, with a focus on increasing sales in the U.S. market, which accounted for 96% of total revenue in the first half of 2026.

Operationally, the company has faced challenges, including a significant increase in total liabilities, which rose to $7.451 million as of June 30, 2026, from $18.695 million at the end of 2025. The company’s cash and cash equivalents decreased sharply to $38,000 from $7.451 million, indicating liquidity pressures. The headcount has also increased as the company invests in its workforce to support growth initiatives. As of June 30, 2026, the company had 2,055,277 shares of common stock outstanding, reflecting its ongoing efforts to raise capital through equity financing.

Looking ahead, Picard Medical has expressed concerns regarding its ability to continue as a going concern, citing the need for additional financing to support operations and product development. The company plans to pursue further equity and debt financing to address its liquidity needs. Management has indicated that while they are optimistic about the growth potential of their products, the path to profitability remains uncertain, and they will need to navigate significant operational and financial challenges in the coming months.